Diagnosis and management of gastrointestinal complications in adult cancer patients: Evidence-based guidelines of the infectious diseases working party (AGIHO) of the german society of hematology and oncology (DGHO)

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1189-1202

  Vehreschild, M J G T ^a   Vehreschild, J J ^a   Hubel K ^a   Hentrich, M ^b   Schmidt hieber, M ^c   Christopeit, M ^d   Maschmeyer, G ^e   Schalk, E ^f   Cornely, O A ^a,g   Neumann, S ^h  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Harlaching Hospital   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^e Ernst von Bergmann Klinikum   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Diarrhea; Enterocolitis; Fever; Gastrointestinal; Neutropenia

Indexed keywords

ACETORPHAN; AMOXICILLIN; ANGIOPEPTIN; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; AZITHROMYCIN; BUDESONIDE; CAPECITABINE; CEFTRIAXONE; CIDOFOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; FIDAXOMICIN; FLUOROURACIL; GANCICLOVIR; GENTAMICIN; IRINOTECAN; LEVOFLOXACIN; LOPERAMIDE; METRONIDAZOLE; NITAZOXANIDE; OCTREOTIDE; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG; VANCOMYCIN;

ADENOVIRUS INFECTION; APLASTIC ANEMIA; BACTERIAL INFECTION; BLOATING; CAMPYLOBACTER ENTERITIS; CANCER PATIENT; CARCINOID; CLOSTRIDIUM DIFFICILE INFECTION; CONSENSUS DEVELOPMENT; CONSERVATIVE TREATMENT; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM DISEASE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; GERMANY; HAND WASHING; HUMAN; LABORATORY TEST; LACTOSE INTOLERANCE; LOW DRUG DOSE; MALABSORPTION; MEDICAL SOCIETY; NEUROENDOCRINE TUMOR; NEUTROPENIC ENTEROCOLITIS; PARANEOPLASTIC DIARRHEA; PARASITOSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ROTAVIRUS INFECTION; SALMONELLOSIS; SHIGELLOSIS; SOLID TUMOR; TREATMENT DURATION; VIRAL GASTROENTERITIS; YERSINIA INFECTION;

ADULT; ANTINEOPLASTIC AGENTS; DIARRHEA; ENTEROCOLITIS; FEVER; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 84877115879     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt001     Document Type: Review

References (168)

1. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32(6): 851-854.
2. Nasir A, Gardner NM, Strosberg J et al. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas 2008; 36(3): 309-313.
3. Udenfriend S, Weissbach H, Sjoerdsma A. Studies on tryptophan and serotonin in patients with malignant carcinoid. Science 1956; 123(3199): 669.
4. Strohm WD. [Paraneoplastic spastic tetraparesis in glucagonoma syndrome. Successful therapy with octreotide, dacarbazine and interferon-alpha]. Z Gastroenterol 1996; 34(7): 438-445.
5. Saban J, Boixeda D, Moreno A et al. Long survival of diarrhea-associated hepatocarcinoma treated with Adriamycin and indomethacin. A case report. Am J Clin Pathol 1986; 86(2): 241-247.
6. Domen RE, Shaffer MB, Jr., Finke J et al. The glucagonoma syndrome. Report of a case. Arch Intern Med 1980; 140(2): 262-263.
7. Interlandi JW, Hundley RF, Kasselberg AG et al. Hypercortisolism, diarrhea with steatorrhea, and massive proteinuria due to pheochromocytoma. South Med J 1985; 78(7): 879-883.
8. Steiner E, Velt P, Gutierrez O et al. Hepatocellular carcinoma presenting with intractable diarrhea. A radiologic-pathologic correlation. Arch Surg 1986; 121(7): 849-851.
9. Winkler AS, Dean A, Hu M et al. Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases. Clin Auton Res 2001; 11(2): 115-118.
10. Ge F, Li ZJ, Cao ZL. Thymoma associated with severe diarrhoea and anaemia. Chin Med J (Engl) 2006; 119(6): 526-528.
11. Sleijfer S, Kaptein A, Versteegh MI et al. Full-blown graft-versus-host disease presenting with skin manifestations, jaundice and diarrhoea: an unusual paraneoplastic phenomenon of a thymoma. Eur J Gastroenterol Hepatol 2003; 15(5): 565-569.
12. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315(11): 663-666.
13. Rubin J, Ajani J, Schirmer W et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17(2): 600-606.
14. NCCN. Neuroendocrine Tumors-Version 1.2012. J Natl Compr Canc Netw 2012; 10: 724-764.
15. O'Toole D, Ducreux M, Bommelaer G et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88(4): 770-776.
16. Aksoy DY, Tanriover MD, Uzun O et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007; 18(1): 183-189.
17. Delaunoit T, Goldberg RM, Sargent DJ et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004; 101(10): 2170-2176.
18. Kuebler JP, Colangelo L, O'Connell MJ et al. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007; 110(9): 1945-1950.
19. Sloan JA, Goldberg RM, Sargent DJ et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20(6): 1491-1498.
20. Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13(1): 210-221.
21. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22(16): 3238-3247.
22. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12(4): 426-437.
23. Lenfers BH, Loeffler TM, Droege CM et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10(10): 1251-1253.
24. Saliba F, Hagipantelli R, Misset JL et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16(8): 2745-2751.
25. Avery R, Pohlman B, Adal K et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000; 25(1): 67-69.
26. Vehreschild MJ, Meissner AM, Cornely OA et al. Clinically defined chemotherapyassociated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 2011; 96(12): 1855-1860.
27. Gorschluter M, Glasmacher A, Hahn C et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33(6): 786-791.
28. Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47(1): 43-50.
29. Owens RC, Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1): S19-S31.
30. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3(5): 563-578.
31. Hickson M, D'Souza AL, Muthu N et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335(7610): 80.
32. Plummer S, Weaver MA, Harris JC et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7(1): 59-62.
33. Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer 1994; 74(5): 1629-1633.
34. Osterlund P, Ruotsalainen T, Peuhkuri K et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2004; 2(8): 696-703.
35. Benson AB, 3rd, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22(14): 2918-2926.
36. Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14(4): 1128-1135.
37. Abigerges D, Armand JP, Chabot GG et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86(6): 446-449.
38. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15(1): 251-260.
39. Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13(1): 222-226.
40. Barbounis V, Koumakis G, Vassilomanolakis M et al. Control of irinotecaninduced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9(4): 258-260.
41. Gebbia V, Carreca I, Testa A et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4(4): 443-445.
42. Kornblau S, Benson AB, Catalano R et al. Management of cancer treatmentrelated diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 2000; 19(2): 118-129.
43. Goumas P, Naxakis S, Christopoulou A et al. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998; 3(1): 50-53.
44. Murphy J, Stacey D, Crook J et al. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. Can Oncol Nurs J 2000; 10(3): 96-100.
45. Qvitzau S, Matzen P, Madsen P. Treatment of chronic diarrhoea: loperamide versus ispaghula husk and calcium. Scand J Gastroenterol 1988; 23(10): 1237-1240.
46. Karthaus M, Ballo H, Abenhardt W et al. Prospective, double-blind, placebocontrolled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005; 68(4-6): 326-332.
47. Schmittel A, Jahnke K, Thiel E et al. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol 2004; 15(8): 1296.
48. Kehrer DF, Sparreboom A, Verweij J et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7(5): 1136-1141.
49. Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008; 42(Suppl 2): S64-70.
50. Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibioticassociated diarrhea. J Clin Gastroenterol 2008; 42(Suppl 2): S58-S63.
51. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40(11): 1625-1634.
52. Mortimer EA, Jr, Lipsitz PJ, Wolinsky E et al. Transmission of staphylococci between newborns. Importance of the hands to personnel. Am J Dis Child 1962; 104: 289-295.
53. Semmelweis IP. Die Aetiologie, der Begriff und die Prophylaxis des Kindbettfiebers. Pest, Wien und Leipzig: CA Hartleben's Verlags-Expedition; 1861.
54. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002; 23(12 Suppl): S3-S40.
55. Altclas J, Requejo A, Jaimovich G et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2002; 34(5): 723.
56. Bilgrami S, Feingold JM, Dorsky D et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23(10): 1039-1042.
57. Dettenkofer M, Ebner W, Bertz H et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant 2003; 31(9): 795-801.
58. Gorschluter M, Marklein G, Hofling K et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol 2002; 117(2): 351-358.
59. Panichi G, Pantosti A, Gentile G et al. Clostridium difficile colitis in leukemia patients. Eur J Cancer Clin Oncol 1985; 21(10): 1159-1163.
60. Schalk E, Bohr UR, Konig B et al. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009; 89(1): 9-14.
61. Reineke J, Tenzer S, Rupnik M et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 2007; 446(7134): 415-419.
62. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359(18): 1932-1940.
63. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31(5): 431-455.
64. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15(13): 1554-1580.
65. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491): 1079-1084.
66. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29(1): 44-50.
67. Dubberke ER, Sadhu J, Gatti R et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol 2007; 28(2): 208-211.
68. Starr JM, Martin H, McCoubrey J et al. Risk factors for Clostridium difficile colonisation and toxin production. Age Ageing 2003; 32(6): 657-660.
69. Gifford AH, Kirkland KB. Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 2006; 25(12): 751-755.
70. Loo VG, Bourgault AM, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365(18): 1693-1703.
71. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1): S12-S18.
72. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15(12): 1067-1079.
73. Crobach MJ, Dekkers OM, Wilcox MH et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15(12): 1053-1066.
74. Deshpande A, Pasupuleti V, Patel P et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011; 9(8): 665-669, e661.
75. O'Connor D, Hynes P, Cormican M et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficileassociated diarrhea. J Clin Microbiol 2001; 39(8): 2846-2849.
76. Ticehurst JR, Aird DZ, Dam LM et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44(3): 1145-1149.
77. Huang H, Weintraub A, Fang H et al. Comparison of a commercial multiplex realtime PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol 2009; 47(11): 3729-3731.
78. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a doubleblind non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 55(suppl 2): S93-S103.
79. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364(5): 422-431.
80. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45(3): 302-307.
81. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14(6): 929-931.
82. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353(23): 2442-2449.
83. Pear SM, Williamson TH, Bettin KM et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120(4): 272-277.
84. Climo MW, Israel DS, Wong ES et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998; 128(12 Pt 1): 989-995.
85. Carling P, Fung T, Killion A et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24(9): 699-706.
86. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006; 40(3): 249-255.
87. Na X, Kelly C. Probiotics in clostridium difficile Infection. J Clin Gastroenterol 2011; 45(Suppl): S154-S158.
88. Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003; 98(2): 354-358.
89. Kato H, Iwashima Y, Nakamura M et al. Inappropriate use of loperamide worsens Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70(2): 194-195.
90. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27(10): 1169-1172.
91. Friedenberg F, Fernandez A, Kaul V et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44(8): 1176-1180.
92. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35(6): 690-696.
93. Gorschluter M, Hahn C, Ziske C et al. Low frequency of enteric infections by Salmonella, Shigella, Yersinia and Campylobacter in patients with acute leukemia. Infection 2002; 30(1): 22-25.
94. Delaloye J, Merlani G, Petignat C et al. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?. Eur J Clin Microbiol Infect Dis 2004; 23(10): 751-758.
95. Gentile G, Venditti M, Micozzi A et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis 1991; 13(5): 842-846.
96. Kamboj M, Mihu CN, Sepkowitz K et al. Work-up for infectious diarrhea after allogeneic hematopoietic stem cell transplantation: single specimen testing results in cost savings without compromising diagnostic yield. Transpl Infect Dis 2007; 9(4): 265-269.
97. Yuen KY, Woo PC, Liang RH et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998; 30(2): 75-81.
98. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989; 321(1): 16-24.
99. Gayraud M, Scavizzi MR, Mollaret HH et al. Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin Infect Dis 1993; 17(3): 405-410.
100. Gupta A, Nelson JM, Barrett TJ et al. Antimicrobial resistance among Campylobacter strains, United States, 1997-2001. Emerg Infect Dis 2004; 10(6): 1102-1109.
101. Wain J, Hoa NT, Chinh NT et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25(6): 1404-1410.
102. Wang JH, Liu YC, Yen MY et al. Mycotic aneurysm due to non-typhi salmonella: report of 16 cases. Clin Infect Dis 1996; 23(4): 743-747.
103. Liakopoulou E, Mutton K, Carrington D et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36(8): 691-694.
104. Ludwig A, Adams O, Laws HJ et al. Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus. J Med Virol 2008; 80(8): 1461-1467.
105. Roddie C, Paul JP, Benjamin R et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49(7): 1061-1068.
106. Mattner F, Sohr D, Heim A et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect 2006; 12(1): 69-74.
107. Sugata K, Taniguchi K, Yui A et al. Analysis of rotavirus antigenemia in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2012; 14(1): 49-56.
108. Rockx B, De Wit M, Vennema H et al. Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis 2002; 35(3): 246-253.
109. Hohne M, Schreier E. Detection and characterization of norovirus outbreaks in Germany: application of a one-tube RT-PCR using a fluorogenic real-time detection system. J Med Virol 2004; 72(2): 312-319.
110. Rabenau HF, Clarici AM, Muhlbauer G et al. Rapid detection of enterovirus infection by automated RNA extraction and real-time fluorescence PCR. J Clin Virol 2002; 25(2): 155-164.
111. Schwartz S, Vergoulidou M, Schreier E et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 2011; 117(22): 5850-5856.
112. Rayani A, Bode U, Habas E et al. Rotavirus infections in paediatric oncology patients: a matched-pairs analysis. Scand J Gastroenterol 2007; 42(1): 81-87.
113. Patel NC, Hertel PM, Estes MK et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362(4): 314-319.
114. Rossignol JF, Abu-Zekry M, Hussein A et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006; 368(9530): 124-129.
115. Kanfer EJ, Abrahamson G, Taylor J et al. Severe rotavirus-associated diarrhoea following bone marrow transplantation: treatment with oral immunoglobulin. Bone Marrow Transplant 1994; 14(4): 651-652.
116. Nicolasora NP, Reddy P, Kaul DR. Biopsy-proven adenoviral diarrhea responding to low-dose cidofovir. Transpl Infect Dis 2008; 10(5): 346-350.
117. Schofield KP, Morris DJ, Bailey AS et al. Gastroenteritis due to adenovirus type 41 in an adult with chronic lymphocytic leukemia. Clin Infect Dis 1994; 19(2): 311-312.
118. Leruez-Ville M, Chardin-Ouachee M, Neven B et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. Bone Marrow Transplant 2006; 38(1): 23-28.
119. Ng AP, Worth L, Chen L et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 2005; 90(12): 1672-1679.
120. Lee MY, Chiou TJ, Hsiao LT et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008; 87(4): 285-289.
121. Cheung WW, Tse E, Leung AY et al. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 2007; 82(2): 108-111.
122. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94(12): 4029-4035.
123. Reed EC, Wolford JL, Kopecky KJ et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112(7): 505-510.
124. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113(23): 5711-5719.
125. Page MJ, Dreese JC, Poritz LS et al. Cytomegalovirus enteritis: a highly lethal condition requiring early detection and intervention. Dis Colon Rectum 1998; 41(5): 619-623.
126. Hackman RC, Wolford JL, Gleaves CA et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. Transplantation 1994; 57(2): 231-237.
127. Kakugawa Y, Kami M, Matsuda T et al. Endoscopic diagnosis of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation. World J Gastroenterol 2010; 16(23): 2907-2912.
128. Ljungman P, de la Camara R, Cordonnier C et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008; 42(4): 227-240.
129. ECIL. Recommendations for CMV and HHV-6 management in patients with hematological diseases. Vol. 2012; 2011. European Conference on Infections in Leukemia, ECIL, Antibes, France.
130. Ljungman P, Cordonnier C, Einsele H et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 1998; 21(5): 473-476.
131. Machado CM, Dulley FL, Boas LS et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26(4): 413-417.
132. Crippa F, Corey L, Chuang EL et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32(2): 214-219.
133. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99(4): 1159-1164.
134. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97(2): 388-392.
135. Platzbecker U, Bandt D, Thiede C et al. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001; 71(7): 880-885.
136. Cesaro S, Zhou X, Manzardo C et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J Clin Virol 2005; 34(2): 129-132.
137. Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct). Bone Marrow Transplant 1996; 18(Suppl 2): 110-114.
138. Mattes FM, Hainsworth EG, Geretti AM et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189(8): 1355-1361.
139. Legrand F, Grenouillet F, Larosa F et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant 2011; 46(6): 858-862.
140. Greaves D, Gouliouris T, O'Donovan M et al. Strongyloides stercoralis hyperinfection in a patient treated for multiple myeloma. Br J Haematol 2012; 158(1): 2.
141. Kobayashi CI, Yamamoto G, Hayashi A et al. Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. Ann Hematol 2011; 90(2): 225-226.
142. Verdier RI, Fitzgerald DW, Johnson WD, Jr et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000; 132(11): 885-888.
143. Hoge CW, Shlim DR, Ghimire M et al. Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet 1995; 345(8951): 691-693.
144. Picardi M, Selleri C, Camera A et al. Early detection by ultrasound scan of severe post-chemotherapy gut complications in patients with acute leukemia. Haematologica 1999; 84(3): 222-225.
145. Cartoni C, Dragoni F, Micozzi A et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol 2001; 19(3): 756-761.
146. Gorschluter M, Mey U, Strehl J et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005; 75(1): 1-13.
147. Gorschluter M, Mey U, Strehl J et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006; 6: 35.
148. Vlasveld LT, Zwaan FE, Fibbe WE et al. Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine. Ann Hematol 1991; 62(4): 129-134.
149. Cunningham SC, Fakhry K, Bass BL et al. Neutropenic enterocolitis in adults: case series and review of the literature. Dig Dis Sci 2005; 50(2): 215-220.
150. Oehadian A, Fadjari TH. Neutropenic enterocolitis in breast cancer patient after taxane-containing chemotherapy. Acta Med Indones 2008; 40(1): 29-33.
151. Kouroussis C, Samonis G, Androulakis N et al. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 2000; 23(3): 309-313.
152. Geisler JP, Schraith DF, Manahan KJ et al. Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. Gynecol Oncol 2004; 92(2): 705-707.
153. Gadducci A, Gargini A, Palla E et al. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. Anticancer Res 2005; 25(3c): 2509-2513.
154. Ferrazzi E, Toso S, Zanotti M et al. Typhlitis (neutropenic enterocolitis) after a single dose of vinorelbine. Cancer Chemother Pharmacol 2001; 47(3): 277-279.
155. Kronawitter U, Kemeny NE, Blumgart L. Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin-a case report. Cancer 1997; 80(4): 656-660.
156. Hayes D, Jr, Leonardo JM. Neutropenic enterocolitis in a woman treated with 5-fluorouracil and leucovorin for colon carcinoma. N C Med J 2002; 63(3): 132-134.
157. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000; 25(12): 1269-1278.
158. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of antiinfective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37(8): 997-1005.
159. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2): S105-S117.
160. Micozzi A, Cartoni C, Monaco M et al. High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Support Care Cancer 1996; 4(4): 294-297.
161. Wade JC, Rubenstein EB. NCCN: Fever and neutropenia. Cancer Control 2001; 8(6 Suppl 2): 16-21.
162. Gerding DN, Muto CA, Owens RC, Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1): S43-S49.
163. Longo WE, Mazuski JE, Virgo KS et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47(10): 1620-1626.
164. Pepin J, Routhier S, Gagnon S et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42(6): 758-764.
165. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97(7): 1769-1775.
166. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80(11): 867-868.
167. Bennish ML, Salam MA, Haider R et al. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162(3): 711-716.
168. Khan WA, Seas C, Dhar U et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126(9): 697-703.